Trial Profile

An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epinephrine (Primary)
Indications Chronic urticaria
Focus Therapeutic Use
Sponsors ARS Pharmaceuticals

Most Recent Events

09 Mar 2026 According to an ARS Pharmaceuticals media release, interim data anticipated in the second half of 2026 followed by the potential initiation of a single pivotal efficacy study in mid-2027
10 Nov 2025 event According to an ARS Pharmaceuticals media release, topline data from this trial anticipated in early 2026.
15 Apr 2025 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com